Medical Device Industry Latest News Report (Updated April 16, 2026)

Domestic News

1. PMDA Initiates Use of Generative AI "Microsoft Copilot" for All Executives and Employees

【Regulatory Trends・Operational Efficiency】
The Pharmaceuticals and Medical Devices Agency (PMDA) announced that it has introduced and commenced the use of Microsoft's generative AI digital assistant, "Microsoft Copilot," for all its executives and employees starting April 2026. This initiative is part of the "PMDA Action Plan for AI Utilization in Operations."

Impact on the Industry: The full-scale adoption of generative AI by PMDA, which is responsible for the review and safety measures of medical devices and pharmaceuticals, is expected to streamline review processes and enhance productivity. In the future, it may also contribute to accelerating the approval application process for companies, making this a notable movement in the promotion of digital transformation (DX) by regulatory authorities.

2. Japan's Only Specialized Exhibition for Medical Device Design and Manufacturing, "Medtec Japan 2026," Approaches

【Events・Industry Trends】
"Medtec Japan 2026," the only specialized exhibition and seminar in Japan for medical device design and manufacturing, will be held from April 21 to 23, 2026, at Tokyo Big Sight. Numerous medical device manufacturers and development engineers from both Japan and abroad will attend to showcase cutting-edge medical device technologies, manufacturing solutions, and innovations.

Impact on the Industry: Together with "ITEM2026," a medical imaging exhibition held concurrently, this event serves as a crucial platform for information exchange in Japan's spring medtech industry. Particularly at Medtec, technology trends covering the entire supply chain, including materials, electronic components, OEM, and AI solutions, will be revealed, making it important for exploring future product development directions.

International News

3. Cala Health Receives FDA Clearance for Next-Generation Wearable Neurostimulation Device "kIQ Plus"

【New Products and Regulatory Trends】
Cala Health, a U.S. company, announced that it has received U.S. FDA (Food and Drug Administration) clearance for its next-generation wearable neurostimulation device, "kIQ Plus," which treats essential tremor and action tremor (hand tremor) associated with Parkinson's disease. This product senses patient-specific tremor patterns and delivers individualized electrical stimulation (TAPS therapy) to the nerves in the wrist to suppress tremors.

Impact on the Industry: Non-invasive wearable neurostimulation therapy is rapidly gaining popularity as a new alternative to pharmacotherapy and surgical procedures. The new model includes additional treatment modes and adaptive calibration, representing a technological innovation that directly improves patients' quality of life (QOL).

4. Phantom Neuro Receives Approval for First "Human Implantable" Neurointerface Clinical Trial

【Technological Innovation and Clinical Trials】
Phantom Neuro, a U.S. company, announced that it has received approval to commence its first-in-human clinical trial in Australia for its muscle-machine interface system, "Phantom X." This system deciphers natural muscle movements through small sensors implanted under the skin, enabling intuitive control of prosthetic limbs and robotic devices.

Impact on the Industry: Progressing from preclinical stages to actual human implantation is a significant milestone in the field of brain-machine interfaces (BMI) and neurointerfaces. This technology, which achieves advanced prosthetic control with a minimally invasive approach, has the potential to dramatically transform motor function recovery for amputees in the future.

5. Medtronic Announces 12-Month Real-World Data for IN.PACT AV Drug-Coated Balloon

【Clinical Data & Business Performance】
Medtronic announced positive 12-month real-world data from its Post-Approval Study of the IN.PACT AV Drug-Coated Balloon (DCB), used for the treatment of arteriovenous fistula (AVF) stenosis in dialysis patients. The results, reported at the Society of Interventional Radiology (SIR) meeting in Toronto, confirmed high efficacy in real-world clinical practice, with a primary patency rate of 70.2% for target lesions, consistent with previous randomized controlled trials (RCTs).

Impact on the Industry: Maintaining vascular access in dialysis patients is a critical challenge. The corroboration of the long-term efficacy and safety of DCBs through real-world data (RWD) further solidifies the position of DCBs as a standard treatment and highlights their superiority over competing products.

6. Boston Scientific Invests $88.4 Million (€75 Million) in Irish R&D Facility

【Business Strategy & Investment】
Boston Scientific announced an investment of €75 million (approximately $88.4 million) to expand its research and development (R&D) capabilities at its facility in Galway, Ireland. This investment will fund the construction of new laboratory spaces, enhancing the design, development, and testing of next-generation medical devices.

Impact on the Industry: This continuous large-scale investment in Ireland, a key medical device hub in Europe, clearly demonstrates Boston Scientific's strategy to strengthen its global supply chain and accelerate innovation. It can be seen as a strategic move to maintain its lead in the competitive development of complex intravascular treatment devices and other medical technologies.

References

• Pharmaceuticals and Medical Devices Agency: Regarding the commencement of using generative AI for PMDA operations (April 15, 2026)
• PR TIMES: Medtec Japan - The only specialized exhibition and seminar in Japan for medical device manufacturing and design
• MassDevice: Cala wins FDA nod for next-gen wearable neurostim tech for essential tremor, Parkinson's
• MassDevice: Phantom Neuro can begin first-in-human neural interface trial
• Medtronic: Medtronic reports strong 12-month real-world outcomes for IN.PACT™ AV drug-coated balloon
• MassDevice: Boston Scientific invests $88.4M to expand R&D in Ireland